Literature DB >> 24094411

Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution.

Moustafa Algamal1, Julijana Milojevic, Naeimeh Jafari, William Zhang, Giuseppe Melacini.   

Abstract

Human serum albumin (HSA) is a potent inhibitor of Aβ self-association and this novel, to our knowledge, function of HSA is of potential therapeutic interest for the treatment of Alzheimer's disease. It is known that HSA interacts with Aβ oligomers through binding sites evenly partitioned across the three albumin domains and with comparable affinities. However, as of this writing, no information is available on the HSA-Aβ interactions beyond domain resolution. Here, we map the HSA-Aβ interactions at subdomain and peptide resolution. We show that each separate subdomain of HSA domain 3 inhibits Aβ self-association. We also show that fatty acids (FAs) compete with Aβ oligomers for binding to domain 3, but the determinant of the HSA/Aβ oligomer interactions are markedly distinct from those of FAs. Although salt bridges with the FA carboxylate determine the FA binding affinities, hydrophobic contacts are pivotal for Aβ oligomer recognition. Specifically, we identified a site of Aβ oligomer recognition that spans the HSA (494-515) region and aligns with the central hydrophobic core of Aβ. The HSA (495-515) segment includes residues affected by FA binding and this segment is prone to self-associate into β-amyloids, suggesting that sites involved in fibrilization may provide a lead to develop inhibitors of Aβ self-association.
Copyright © 2013 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AD; Alzheimer’s Disease; BBB; Blood Brain Barrier; CNS; CSF; Central Nervous System; Cerebrospinal Fluid; FA; Fatty Acid; HSA; Human Serum Albumin; ICP; Inductively Coupled Plasma; MA; Myristic Acid; RC; Random Coil; SL; STD; STR; Saturation Transfer Difference; Saturation Transfer Reference; Spin-Lock; WG; Watergate water-suppression NMR technique

Mesh:

Substances:

Year:  2013        PMID: 24094411      PMCID: PMC3791307          DOI: 10.1016/j.bpj.2013.08.025

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  37 in total

1.  Expression, refolding, and isotopic labeling of human serum albumin domains for NMR spectroscopy.

Authors:  H Mao; A H Gunasekera; S W Fesik
Journal:  Protein Expr Purif       Date:  2000-12       Impact factor: 1.650

Review 2.  Apolipoprotein J (clusterin) and Alzheimer's disease.

Authors:  M Calero; A Rostagno; E Matsubara; B Zlokovic; B Frangione; J Ghiso
Journal:  Microsc Res Tech       Date:  2000-08-15       Impact factor: 2.769

3.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Aβ association inhibition by transferrin.

Authors:  Annie V Raditsis; Julijana Milojevic; Giuseppe Melacini
Journal:  Biophys J       Date:  2013-07-16       Impact factor: 4.033

5.  MOLMOL: a program for display and analysis of macromolecular structures.

Authors:  R Koradi; M Billeter; K Wüthrich
Journal:  J Mol Graph       Date:  1996-02

6.  Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.

Authors:  I Petitpas; T Grüne; A A Bhattacharya; S Curry
Journal:  J Mol Biol       Date:  2001-12-14       Impact factor: 5.469

7.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

8.  ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.

Authors:  Joyce W Lustbader; Maurizio Cirilli; Chang Lin; Hong Wei Xu; Kazuhiro Takuma; Ning Wang; Casper Caspersen; Xi Chen; Susan Pollak; Michael Chaney; Fabrizio Trinchese; Shumin Liu; Frank Gunn-Moore; Lih-Fen Lue; Douglas G Walker; Periannan Kuppusamy; Zay L Zewier; Ottavio Arancio; David Stern; Shirley ShiDu Yan; Hao Wu
Journal:  Science       Date:  2004-04-16       Impact factor: 47.728

9.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

Review 10.  Clearing amyloid through the blood-brain barrier.

Authors:  Berislav V Zlokovic
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

View more
  14 in total

1.  Atomic-resolution map of the interactions between an amyloid inhibitor protein and amyloid β (Aβ) peptides in the monomer and protofibril states.

Authors:  Moustafa Algamal; Rashik Ahmed; Naeimeh Jafari; Bilal Ahsan; Joaquin Ortega; Giuseppe Melacini
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

2.  Fatty Acids Compete with Aβ in Binding to Serum Albumin by Quenching Its Conformational Flexibility.

Authors:  Cong Guo; Huan-Xiang Zhou
Journal:  Biophys J       Date:  2018-12-06       Impact factor: 4.033

3.  Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies.

Authors:  Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  J Biol Chem       Date:  2017-09-18       Impact factor: 5.157

4.  Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.

Authors:  Stephen Boulton; Rajeevan Selvaratnam; Rashik Ahmed; Katherine Van; Xiaodong Cheng; Giuseppe Melacini
Journal:  J Med Chem       Date:  2019-05-10       Impact factor: 7.446

5.  Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.

Authors:  Allison M Bradbury; Heather L Gray-Edwards; Jamie L Shirley; Victoria J McCurdy; Alexandria N Colaco; Ashley N Randle; Pete W Christopherson; Allison C Bird; Aime K Johnson; Diane U Wilson; Judith A Hudson; Nicholas L De Pompa; Donald C Sorjonen; Brandon L Brunson; Mylvaganam Jeyakumar; Frances M Platt; Henry J Baker; Nancy R Cox; Miguel Sena-Esteves; Douglas R Martin
Journal:  Exp Neurol       Date:  2014-10-05       Impact factor: 5.330

Review 6.  Albumin nanostructures as advanced drug delivery systems.

Authors:  Mahdi Karimi; Sajad Bahrami; Soodeh Baghaee Ravari; Parham Sahandi Zangabad; Hamed Mirshekari; Mahnaz Bozorgomid; Somayeh Shahreza; Masume Sori; Michael R Hamblin
Journal:  Expert Opin Drug Deliv       Date:  2016-06-03       Impact factor: 6.648

7.  Noncanonical protein kinase A activation by oligomerization of regulatory subunits as revealed by inherited Carney complex mutations.

Authors:  Naeimeh Jafari; Jason Del Rio; Madoka Akimoto; Jung Ah Byun; Stephen Boulton; Kody Moleschi; Yousif Alsayyed; Pascale Swanson; Jinfeng Huang; Karla Martinez Pomier; Chi Lee; Jian Wu; Susan S Taylor; Giuseppe Melacini
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

8.  Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid.

Authors:  Ava Faridi; Wen Yang; Hannah Gabrielle Kelly; Chuanyu Wang; Pouya Faridi; Anthony Wayne Purcell; Thomas P Davis; Pengyu Chen; Stephen J Kent; Pu Chun Ke
Journal:  Biomacromolecules       Date:  2019-10-22       Impact factor: 6.978

9.  Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner.

Authors:  Sandeep K Sharma; Erik Chorell; Pär Steneberg; Emma Vernersson-Lindahl; Helena Edlund; Pernilla Wittung-Stafshede
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

10.  Neuronal uptake of serum albumin is associated with neuron damage during the development of epilepsy.

Authors:  Zanhua Liu; Jinjie Liu; Suping Wang; Sibo Liu; Yongbo Zhao
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.